---
title: "This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289082529.md"
description: "Wall Street analysts downgraded two stocks: HC Wainwright & Co. lowered ADC Therapeutics (ADCT) from Buy to Neutral, while Wells Fargo cut W. R. Berkley (WRB) from Equal-Weight to Underweight and reduced its price target to $58."
datetime: "2026-06-08T16:13:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289082529.md)
  - [en](https://longbridge.com/en/news/289082529.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289082529.md)
---

# This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   HC Wainwright & Co. analyst Robert Burns downgraded **ADC Therapeutics SA** (NYSE:ADCT) from Buy to Neutral. ADC Therapeutics shares closed at $1.0250 on Friday. See how other analysts view this stock.
-   Wells Fargo analyst Elyse Greenspan downgraded **W. R. Berkley Corporation** (NYSE:WRB) from Equal-Weight to Underweight and lowered the price target from $64 to $58. WR Berkley shares closed at $68.57 on Friday. See how other analysts view this stock.

Considering buying ADCT stock? Here’s what analysts think:

_Photo via Shutterstock_

### Related Stocks

- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)
- [WRB.US](https://longbridge.com/en/quote/WRB.US.md)
- [WRB-G.US](https://longbridge.com/en/quote/WRB-G.US.md)
- [WRB-E.US](https://longbridge.com/en/quote/WRB-E.US.md)
- [WRB-H.US](https://longbridge.com/en/quote/WRB-H.US.md)
- [WRB-F.US](https://longbridge.com/en/quote/WRB-F.US.md)

## Related News & Research

- [W.R. Berkley FY26 H1 net income rises 18.15% to $967.48 million; revenue increases 12.9% to $291 million](https://longbridge.com/en/news/294551618.md)
- [W.R. Berkley names Christopher Moede president of Berkley Risk](https://longbridge.com/en/news/294108254.md)
- [W.R. Berkley names Daniel Westcott executive vice president](https://longbridge.com/en/news/293970718.md)
- [Analyst Backs Crescent Biopharma With Buy Rating on Advancing ADC Pipeline and Strong Cash Runway](https://longbridge.com/en/news/294417283.md)
- [Adlai Nortye Initiated With Buy on Differentiated RAS-Targeting Pipeline, ADC Strategy and Solid Cash Runway](https://longbridge.com/en/news/293951548.md)